Maruho Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Maruho Co., Ltd.
The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen.
Upstream Bio acquired Phase Ib-ready UPB-101 from Astellas, and its experienced team plans to buy additional drug candidates for the treatment of allergic and inflammatory diseases.
Ahead of pending regulatory decisions on both sides of the Atlantic for Opzelura, Incyte has reported promising progress for the JAK inhibitor in the highly competitive atopic dermatitis market.
The latest batch of new drug approvals in Japan includes several products receiving their first marketing clearances globally, notably a new oral competitor to a blockbuster ulcerative colitis drug and a high-need therapy for the rare disease ASMD.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.